Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Biotech’s Hand, Foot and Mouth Vaccine Succeeds in Phase III Trial

publication date: Mar 14, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech, a vaccine maker headquartered in Beijing, reported positive, though preliminary top-line data from the Phase III clinical trial for its Enterovirus 71 vaccine, a human innoculation that protects against hand, foot and mouth disease. The vaccine, which was administered to infants from 6 to 35 months, produced an efficacy of 95.4%. More details....

Stock Symbol: (NSDQ: SVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors